Bharat Parenterals Limited has shared its Investor Presentation for the quarter ended June 30, 2025, offering insights into its financial performance and strategic direction.

For Q1 FY26, consolidated revenue from operations increased by 25.4% to 116.00 Cr, with EBITDA surging by 206.9% to 13.78 Cr.

The company projects 12-14% standalone revenue growth for FY26, targeting 15-17% EBITDA margins.

Subsidiaries Innoxel and Varenyam Healthcare are expected to achieve revenues of 65-70 Cr and 60-65 Cr respectively in FY26, indicating strategic expansion.

This presentation is crucial for investors tracking the company's operational progress and future growth prospects.